Top Publications from FY17 Based on Impact Factor

  1. Darwich AS; Ogungbenro K; Vinks AA; Powell JR; Reny JL; Marsousi N; Daali Y; Fairman D; Cook J; Lesko LJ. Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future. Clinical Pharmacology and Therapeutics. 2017; 101:646-656.
  2. Ramsey LB; Mizuno T; Vinks AA; Margolis PA. Learning Health Systems as Facilitators of Precision Medicine. Clinical Pharmacology and Therapeutics. 2017; 101:359-367.
  3. Vinks AA. Precision Medicine-Nobody Is Average. Clinical Pharmacology and Therapeutics. 2017; 101:304-307.
  4. Downes KJ; Dong M; Fukuda T; Clancy JP; Haffner C; Bennett MR; Vinks AA; Goldstein SL. Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis. Journal of Antimicrobial Chemotherapy. 2017; 72:254-260.
  5. Yu T; Enioutina EY; Brunner HI; Vinks AA; Sherwin CM. Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus. Clinical Pharmacokinetics. 2017; 56:107-125.
  6. Marsh RA; Fukuda T; Emoto C; Neumeier L; Khandelwal P; Chandra S; Teusink-Cross A; Vinks AA; Mehta PA. Pretransplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab. Biology of Blood and Marrow Transplantation. 2017; 23:635-641.
  7. Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 2016; 22:2220-2225.
  8. Khandelwal P; Fukuda T; Mizuno K; Teusink-Cross A; Mehta PA; Marsh RA; Kashuba ADM; Vinks AA; Davies SM. A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. Biology of Blood and Marrow Transplantation. 2016; 22:1829-1835.
  9. Miyake M; Minami T; Yamazaki H; Emoto C; Mukai T; Toguchi H. Arachidonic acid with taurine enhances pulmonary absorption of macromolecules without any serious histopathological damages. European Journal of Pharmaceutics and Biopharmaceutics. 2017; 114:22-28.
  10. Mizuno T; Fukuda T; Christians U; Perentesis JP; Fouladi M; Vinks AA. Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. British Journal of Clinical Pharmacology. 2017; 83:1097-1107.
  11. Chidambaran V; Venkatasubramanian R; Zhang X; Martin LJ; Niu J; Mizuno T; Fukuda T; Meller J; Vinks AA; Sadhasivam S. ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and morphine pharmacokinetics in children. The Pharmacogenomics Journal. 2017; 17:162-169.
  12. Miyake M; Koga T; Kondo S; Yoda N; Emoto C; Mukai T; Toguchi H. Prediction of drug intestinal absorption in human using the Ussing chamber system: A comparison of intestinal tissues from animals and humans. European Journal of Pharmaceutical Sciences. 2017; 96:373-380.
  13. Cvijanovich NZ; King JC; Flori HR; Gildengorin G; Vinks AA; Wong HR. Safety and Dose Escalation Study of Intravenous Zinc Supplementation in Pediatric Critical Illness. Journal of Parenteral and Enteral Nutrition. 2016; 40:860-868.
  14. Hahn D; Emoto C; Vinks AA; Fukuda T. Developmental Changes in Hepatic Organic Cation Transporter OCT1 Protein Expression from Neonates to Children. Drug metabolism and disposition: the biological fate of chemicals. 2017; 45:23-26.
  15. Balyan R; Zhang X; Chidambaran V; Martin LJ; Mizuno T; Fukuda T; Vinks AA; Sadhasivam S. OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children. Pharmacogenomics. 2017; 18:621-629.
  16. Balyan R; Mecoli M; Venkatasubramanian R; Chidambaran V; Kamos N; Clay S; Moore DL; Mavi J; Glover CD; Szmuk P. CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients. Pharmacogenomics. 2017; 18:337-348.
  17. Chidambaran V; Pilipenko V; Spruance K; Venkatasubramanian R; Niu J; Fukuda T; Mizuno T; Zhang K; Kaufman K; Vinks AA. Fatty acid amide hydrolase-morphine interaction influences ventilatory response to hypercapnia and postoperative opioid outcomes in children. Pharmacogenomics. 2017; 18:143-156.
  18. Chen Y; Lu J; Dong M; Wu D; Zhu Y; Li Q; Chen C; Li Z. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants. European Journal of Clinical Pharmacology. 2016; 72:1479-1488.
  19. Rohan JM; Fukuda T; Alderfer MA; Wetherington Donewar C; Ewing L; Katz ER; Muriel AC; Vinks AA; Drotar D. Measuring Medication Adherence in Pediatric Cancer: An Approach to Validation. Journal of Pediatric Psychology. 2017; 42:jsw039.
  20. Emoto C; Vinks AA; Fukuda T. Risk Assessment of Drug-Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant Patients. Therapeutic Drug Monitoring. 2016; 38:607-613.
  21. Diwan TS; Lichvar AB; Leino AD; Vinks AA; Christians U; Shields AR; Cardi MA; Fukuda T; Mizuno T; Kaiser T. Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve gastrectomy. Clinical Transplantation. 2017; 31:e12975.
  22. Emoto C; Fukuda T; Johnson TN; Neuhoff S; Sadhasivam S; Vinks AA. Characterization of contributing factors to variability in morphine clearance through PBPK modeling implemented with OCT1 transporter. CPT: Pharmacometrics and Systems Pharmacology. 2017; 6:110-119.
  23. Emoto C; Fukuda T; Mizuno T; Schniedewind B; Christians U; Adams DM; Vinks AA. Characterizing the developmental trajectory of sirolimus clearance in neonates and infants. CPT: Pharmacometrics and Systems Pharmacology. 2016; 5:411-417.